{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=47", "query": { "intervention": "Control Study Product", "page": 47 }, "page_size": 10 }, "pagination": { "page": 47, "page_size": 10, "total_count": 4234, "total_pages": 424, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=48&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Study+Product&page=46&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T10:50:34.574Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02585778", "title": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2015-10-23", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 29, "location_summary": "Encino, California • Fresno, California • Oakland, California + 25 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02585778" }, { "nct_id": "NCT05171335", "title": "Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Transcatheter Arterial Chemoembolization", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-08-20", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05171335" }, { "nct_id": "NCT03818321", "title": "Urinary Track Infection Prevention After Urogynecological Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urinary Tract Infections", "Urinary Retention Postoperative", "Pelvic Organ Prolapse" ], "interventions": [ { "name": "Methenamine Hippurate 1 g tablet", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TriHealth Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 185, "start_date": "2019-06-17", "completion_date": "2021-07-01", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03818321" }, { "nct_id": "NCT02648347", "title": "Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Non-Dialysis-Dependent Chronic Kidney Disease" ], "interventions": [ { "name": "Vadadustat", "type": "DRUG" }, { "name": "Darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Akebia Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1751, "start_date": "2015-12", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-06-27", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 208, "location_summary": "Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648347" }, { "nct_id": "NCT05639543", "title": "FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alcohol Associated Hepatitis" ], "interventions": [ { "name": "INT-787", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 67, "start_date": "2022-12-15", "completion_date": "2026-02-10", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 20, "location_summary": "Fresno, California • Palo Alto, California • Sacramento, California + 17 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05639543" }, { "nct_id": "NCT02312115", "title": "Delayed Renal Allograft Function and Furosemide Treatment", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Delayed Graft Function" ], "interventions": [ { "name": "Furosemide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loma Linda University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-09", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-11-25", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02312115" }, { "nct_id": "NCT00355264", "title": "Safety and Efficacy Study of Phenoptin in Subjects With Hyperphenylalaninemia Due to BH4 Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tetrahydrobiopterin Deficiencies", "Hyperphenylalaninemia, Non-Phenylketonuric" ], "interventions": [ { "name": "Phenoptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioMarin Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2006-08", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2020-09-25", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 9, "location_summary": "Los Angeles, California • Chicago, Illinois • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00355264" }, { "nct_id": "NCT01747148", "title": "Testing the AVI-7100 Flu Drug in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "AVI-7100 versus placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 66, "start_date": "2012-12-08", "completion_date": "2016-06-29", "has_results": false, "last_update_posted_date": "2017-12-26", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01747148" }, { "nct_id": "NCT02542215", "title": "Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oral Mucositis" ], "interventions": [ { "name": "Cobiprostone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard Care - Chemotherapy", "type": "DRUG" }, { "name": "Standard Care - Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sucampo Pharma Americas, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2015-06", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2019-12-02", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 76, "location_summary": "Birmingham, Alabama • Peoria, Arizona • Yuma, Arizona + 72 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02542215" }, { "nct_id": "NCT07764978", "title": "Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Newly Diagnosed Multiple Myeloma" ], "interventions": [ { "name": "AZD0120", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "BIOLOGICAL" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Isatuximab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2026-06-26", "completion_date": "2034-05-12", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-25T10:50:34.574Z", "location_count": 45, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07764978" } ] }